Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Propofol vs Dexmedetomidine for Sedation in ERCP
NCT06409104Completed
- Sponsor
- National Cancer Institute
- Start
- Sep 2023
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, single-blind trial of dexmedetomidine in Pancreatobiliary Diseases (2 arms), sponsored by National Cancer Institute. Primary endpoint: Bispectral Index sedation Score. Started Sep 2023; status: completed.
02
Drugs
dexmedetomidine
03
Conditions
Pancreatobiliary Diseases
Beyond the preview
Go deeper on NCT06409104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06409104.